TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03 February 27, 2026
BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates February 27, 2026
Boehringer Ingelheim licenses novel oral therapeutics program for immune diseases from Sitryx Therapeutics February 26, 2026
Crystalys Therapeutics Appoints Tim Walbert, Former Horizon Therapeutics CEO, as Independent Board Director February 11, 2026
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis February 10, 2026
